{"id":319,"date":"2013-07-19T16:25:00","date_gmt":"2013-07-19T07:25:00","guid":{"rendered":"http:\/\/120.29.164.89\/?p=319"},"modified":"2023-08-29T10:32:57","modified_gmt":"2023-08-29T01:32:57","slug":"319","status":"publish","type":"post","link":"https:\/\/www.peptide.co.jp\/en\/new-product\/319.html","title":{"rendered":"RFamide-Related Peptide-1"},"content":{"rendered":"<p><b>Novel Neuropeptide with the carboxyl C-terminal Arg-Phe-NH<sub>2<\/sub>!<\/b><\/p>\n<p>Among peptides with the carboxyl (C)-terminal Arg-Phe-NH<sub>2<\/sub> (RFamide family of peptides), FMRF-Amide (code 4142-v) was first isolated from Mollusks in 1977 [<i>Science,<\/i> <b>197<\/b>, 670 (1977) ]. Another member of this family, Leu-Pro-Leu-Arg-Phe-NH<sub>2<\/sub> (code 4144), was identified in chicken brain in 1983, yet there had not been any reports of corresponding mammalian peptides with the same five C-terminal residues. Recently, a new related peptide was deduced from a human database search by elucidating its endogenous form through application of peptide\/DNA chemistry. The name of the target peptide is RFamide-related peptide-1 (RFRP-1).<\/p>\n<p><img loading=\"lazy\" src=\"\/wp-content\/uploads\/2013\/07\/RFRP-1.gif\" alt=\"RFRP-1\" width=\"449\" height=\"103\" class=\"alignnone size-full wp-image-2242\" \/><\/p>\n<p>Human RFRP-1 was first predicted to be a 12 amino acid residue peptide. Subsequent synthesis and biochemical studies found it to be a ligand for the orphan receptor, OT7T022 (also called FF1)[<i>Nat. Cell Biol.,<\/i> <b>2<\/b>, 703 (2000) ]. Later, the endogenous form of human <a href=\"\/en\/catalog\/f-cat?k_code=4380-s\">RFRP-1 <\/a> was determined to be composed of 37 amino acid residues including the above 12-residue peptide at its C-terminus[<i>Biochim. Biophys. Acta.,<\/i> <b>1540<\/b>, 221 (2001) ]. The same peptide was isolated by another group who named it NPSF(1-37)[<i>J. Biol. Chem.,<\/i> <b>276<\/b>, 36961 (2001) ]. Human RFRP-1 inhibits forskolin-stimulated cAMP production in CHO cells expressing OT7T022 (ED<sub>50<\/sub>=21 nM). The potency is slightly less than that of the 12-residue peptide (ED<sub>50<\/sub>=4.9 nM), however, this result suggests that the C-terminal portion of RFRP-1 is responsible for the recognition of OT7T022. Immunoreactive RFRP-1 was observed in the central nervous system (CNS), with the highest amount detected in the hypothalamus. Specific receptors of RFRP-1, OT7T022 or FF1, have been found in the CNS. It is interesting to note that the synthetic peptide composed of 12 amino acid residues described above has shown prolactin-releasing activity at 10 nM [<i>Nat. Cell Biol.,<\/i> <b>2<\/b>, 703 (2000) ] and that rat NPSF(1-37) has the anti-opioid effect in two models of nociception at 1.0 nmol\/rat [<i>J. Biol. Chem.,<\/i> <b>276<\/b>, 36961 (2001) ].<\/p>\n<p>This new synthetic product RFRP-1 should serve as an important biochemical tool to further research investigations.<\/p>\n<table style=\"width: 90%\" border=\"1\">\n<tbody>\n<tr>\n<td align=\"center\">Code<\/td>\n<td align=\"center\">Compound<\/td>\n<td align=\"center\">Package<\/td>\n<\/tr>\n<tr>\n<td><a href=\"\/en\/catalog\/f-cat?k_code=4380-s\">4380-s<\/a><\/td>\n<td>RFamide-Related Peptide-1 (Human)<\/td>\n<td align=\"center\">0.1 mg vial<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Related Products<\/p>\n<table style=\"width: 90%\" border=\"1\">\n<tbody>\n<tr align=\"center\">\n<td>Code<\/td>\n<td>Compound<\/td>\n<td>Package<\/td>\n<\/tr>\n<tr>\n<td><a href=\"\/en\/catalog\/f-cat?k_code=4142-v\">4142-v<\/a><\/td>\n<td>FMRF-Amide<\/td>\n<td align=\"center\">0.5 mg vial<\/td>\n<\/tr>\n<tr>\n<td><a href=\"\/en\/catalog\/f-cat?k_code=4144\">4144<\/a><\/td>\n<td>Leu-Pro-Leu-Arg-Phe-NH<sub>2<\/sub><\/td>\n<td align=\"center\">25 mg bulk<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Novel Neuropeptide with the carboxyl C-terminal Arg-Phe-NH2!<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/319"}],"collection":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/comments?post=319"}],"version-history":[{"count":2,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/319\/revisions"}],"predecessor-version":[{"id":4949,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/319\/revisions\/4949"}],"wp:attachment":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/media?parent=319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/categories?post=319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/tags?post=319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}